GSK_ Annual_Report_2021-22

GlaxoSmithKline Pharmaceuticals Limited | Annual Report 2021-22 Notes to the Consolidated Financial Statements for the year ended March 31, 2022 226 d) Shares held by subsidiaries of ultimate holding Group in aggregate As at March 31, 2022 As at March 31, 2021 Number of Shares ` in lakhs Number of Shares ` in lakhs Equity shares of ` 10 each (representing 75.00% of total shareholding) 12,70,54,524 127,05.46 12,70,54,524 127,05.46 e) Details of equity shares held by shareholders holding more than 5% shares of the aggregate shares in the Group: As at March 31, 2022 As at March 31, 2021 Number of Shares % Shareholding Number of Shares % Shareholding Glaxo Group Limited, U.K. 6,09,70,500 35.99% 6,09,70,500 35.99% GlaxoSmithKline Pte Limited, Singapore 4,76,04,024 28.10% 4,76,04,024 28.10% Eskaylab Limited, U.K. 1,17,60,000 6.94% 1,17,60,000 6.94% Life Insurance Corporation of India 76,95,698 4.54% 80,91,878 4.78% Note 18 : Other equity ( ` in lakhs ) As at March 31, 2022 As at March 31, 2021 Capital redemption reserve 2,62.00 2,62.00 General reserve 778,50.29 778,50.29 Capital reserve (Refer Note 57) (19,07.01) (19,11.01) Retained earnings (Including Other Comprehensive Income) 1731,49.70 546,84.11 2493,54.98 1308,85.39 Note 19 : Non-current financial liabilities - Lease liabilities ( ` in lakhs ) As at March 31, 2022 As at March 31, 2021 Lease liabilities (Refer Note 48) 7,62.35 20,24.99 7,62.35 20,24.99 Note 20 : Non-current financial liabilities - Others ( ` in lakhs ) As at March 31, 2022 As at March 31, 2021 Security deposits received (Unsecured) 2,05.09 2,05.09 Other non-current financial liabilities 0.72 0.72 2,05.81 2,05.81 Note 21 : Non-current provisions ( ` in lakhs ) As at March 31, 2022 As at March 31, 2021 For Pricing matters (Refer Note 28 ,42 and 44) 123,96.15 123,96.15 For employee benefits (Refer Note 40) - - Gratuity 17,68.11 16,98.96 Leave encashment and compensated absences 36,74.38 34,94.48 Post retirement medical and other benefits 61,78.92 62,85.22